Published in Ann Thorac Surg on November 01, 2006
Follicular dendritic cell sarcoma of the head and neck: Case report, literature review, and pooled analysis of 97 cases. Head Neck (2015) 0.87
Dendritic cell tumor in a salivary gland lymph node: a rare differential diagnosis of salivary gland neoplasms. Diagn Pathol (2011) 0.85
Completely resected follicular dendritic cell sarcoma of the posterior mediastinum: report of a case. Surg Case Rep (2016) 0.75
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Critical care medicine in the United States 2000-2005: an analysis of bed numbers, occupancy rates, payer mix, and costs. Crit Care Med (2010) 6.26
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res (2005) 5.44
Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med (2008) 5.30
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Critical care medicine in the United States: addressing the intensivist shortage and image of the specialty. Crit Care Med (2013) 4.76
Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med (2006) 4.71
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol (2010) 4.01
Critical care medicine in the United States 1985-2000: an analysis of bed numbers, use, and costs. Crit Care Med (2004) 3.62
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer (2008) 3.10
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg (2008) 2.93
Results of chest wall resection and reconstruction with and without rigid prosthesis. Ann Thorac Surg (2006) 2.77
A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J (2005) 2.71
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature (2010) 2.65
American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol (2007) 2.41
Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg (2007) 2.37
Has survival increased in cancer patients admitted to the ICU? Yes. Intensive Care Med (2014) 2.35
Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer (2011) 2.34
Use of video-assisted thoracic surgery for lobectomy in the elderly results in fewer complications. Ann Thorac Surg (2008) 2.33
Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg (2009) 2.32
Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol (2007) 2.23
Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol (2004) 2.22
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19
Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol (2005) 2.12
The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med (2007) 2.12
Video-assisted thoracoscopic surgery (VATS) lobectomy: catastrophic intraoperative complications. J Thorac Cardiovasc Surg (2011) 2.11
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A (2003) 2.09
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol (2009) 2.07
Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol (2003) 2.04
Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg (2006) 2.03
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer (2008) 1.99
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res (2009) 1.99
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol (2013) 1.99
The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg (2004) 1.97
Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol (2003) 1.94
Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res (2008) 1.89
Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg (2009) 1.88
Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist (2008) 1.85
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol (2005) 1.82
Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer (2006) 1.82
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res (2007) 1.79
Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer (2006) 1.79
Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg (2007) 1.75
Critical care medicine use and cost among Medicare beneficiaries 1995-2000: major discrepancies between two United States federal Medicare databases. Crit Care Med (2007) 1.73
Endoscopic retrograde dilation of completely occlusive esophageal strictures. Ann Thorac Surg (2006) 1.71
A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer (2011) 1.70
The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg (2006) 1.70
KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res (2009) 1.69
Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases. J Thorac Oncol (2011) 1.69
Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest (2007) 1.66
Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer (2010) 1.64
A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res (2008) 1.64
Brugada electrocardiographic pattern in a postoperative patient. Crit Care Med (2005) 1.64
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst (2008) 1.63
Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res (2004) 1.63
Extranodal follicular dendritic cell sarcoma: clinical, pathologic, and histogenetic characteristics of an underrecognized disease entity. Virchows Arch (2006) 1.62
Predictors of outcomes after surgical treatment of synchronous primary lung cancers. J Thorac Oncol (2010) 1.61
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer (2012) 1.57
Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res (2007) 1.57
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol (2005) 1.55
The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg (2004) 1.55
Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. Cancer (2008) 1.53
NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. J Natl Compr Canc Netw (2004) 1.50
Smoking and timing of cessation: impact on pulmonary complications after thoracotomy. Chest (2005) 1.49
Structure, process, and annual ICU mortality across 69 centers: United States Critical Illness and Injury Trials Group Critical Illness Outcomes Study. Crit Care Med (2014) 1.48
18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med (2006) 1.46
A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol (2008) 1.43
IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. J Pathol (2010) 1.43
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer (2011) 1.41
Utilization of critical care services among patients undergoing total hip and knee arthroplasty: epidemiology and risk factors. Anesthesiology (2012) 1.41
Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol (2004) 1.41
Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol (2002) 1.41
Innovative designs for the smart ICU: part 1: from initial thoughts to occupancy. Chest (2014) 1.38
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol (2009) 1.38
Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. J Natl Cancer Inst (2010) 1.36
Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med (2007) 1.36
High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes Chromosomes Cancer (2011) 1.35
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer (2013) 1.32
Management of major hemorrhage during mediastinoscopy. J Thorac Cardiovasc Surg (2003) 1.32
Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol (2007) 1.32
Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res (2011) 1.31
Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer (2011) 1.31
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol (2010) 1.31
Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer (2009) 1.30
Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid (2007) 1.29
Changes in critical care beds and occupancy in the United States 1985-2000: Differences attributable to hospital size. Crit Care Med (2006) 1.27
Premortem clinical diagnoses and postmortem autopsy findings: discrepancies in critically ill cancer patients. Crit Care (2007) 1.26
Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol (2009) 1.25